261 related articles for article (PubMed ID: 15694871)
1. Are mu-opioid receptor polymorphisms important for clinical opioid therapy?
Lötsch J; Geisslinger G
Trends Mol Med; 2005 Feb; 11(2):82-9. PubMed ID: 15694871
[TBL] [Abstract][Full Text] [Related]
2. Relevance of frequent mu-opioid receptor polymorphisms for opioid activity in healthy volunteers.
Lötsch J; Geisslinger G
Pharmacogenomics J; 2006; 6(3):200-10. PubMed ID: 16415919
[TBL] [Abstract][Full Text] [Related]
3. Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action.
Lötsch J; Skarke C; Wieting J; Oertel BG; Schmidt H; Brockmöller J; Geisslinger G
Clin Pharmacol Ther; 2006 Jan; 79(1):72-89. PubMed ID: 16413243
[TBL] [Abstract][Full Text] [Related]
4. The mu-opioid receptor gene polymorphism 118A>G depletes alfentanil-induced analgesia and protects against respiratory depression in homozygous carriers.
Oertel BG; Schmidt R; Schneider A; Geisslinger G; Lötsch J
Pharmacogenet Genomics; 2006 Sep; 16(9):625-36. PubMed ID: 16906017
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenetics in pain management: the clinical need.
Webster LR
Clin Lab Med; 2008 Dec; 28(4):569-79. PubMed ID: 19059063
[TBL] [Abstract][Full Text] [Related]
6. [Individual differences in analgesic effects of narcotics].
Ide S; Kasai S; Ikeda K
Nihon Shinkei Seishin Yakurigaku Zasshi; 2008 Feb; 28(1):43-8. PubMed ID: 18411709
[TBL] [Abstract][Full Text] [Related]
7. How individual sensitivity to opiates can be predicted by gene analyses.
Ikeda K; Ide S; Han W; Hayashida M; Uhl GR; Sora I
Trends Pharmacol Sci; 2005 Jun; 26(6):311-7. PubMed ID: 15925706
[TBL] [Abstract][Full Text] [Related]
8. The A118G single nucleotide polymorphism of the mu-opioid receptor gene (OPRM1) is associated with pressure pain sensitivity in humans.
Fillingim RB; Kaplan L; Staud R; Ness TJ; Glover TL; Campbell CM; Mogil JS; Wallace MR
J Pain; 2005 Mar; 6(3):159-67. PubMed ID: 15772909
[TBL] [Abstract][Full Text] [Related]
9. Association of mu-opioid receptor gene polymorphism (A118G) with variations in morphine consumption for analgesia after total knee arthroplasty.
Chou WY; Yang LC; Lu HF; Ko JY; Wang CH; Lin SH; Lee TH; Concejero A; Hsu CJ
Acta Anaesthesiol Scand; 2006 Aug; 50(7):787-92. PubMed ID: 16879459
[TBL] [Abstract][Full Text] [Related]
10. [Genetic polymorphisms and human sensitivity to pain and opioids].
Nishizawa D; Nagashima M; Satoh Y; Tagami M; Ikeda K
Masui; 2009 Sep; 58(9):1093-101. PubMed ID: 19764431
[TBL] [Abstract][Full Text] [Related]
11. [Are polymorphisms in the mu-opioid receptor important for opioid therapy?].
Lötsch J; Freynhagen R; Geisslinger G
Schmerz; 2005 Oct; 19(5):378-82, 384-5. PubMed ID: 16133302
[TBL] [Abstract][Full Text] [Related]
12. Association of morphine-induced antinociception with variations in the 5' flanking and 3' untranslated regions of the mu opioid receptor gene in 10 inbred mouse strains.
Shigeta Y; Kasai S; Han W; Hata H; Nishi A; Takamatsu Y; Hagino Y; Yamamoto H; Koide T; Shiroishi T; Kasai K; Tsunashima K; Kato N; Ikeda K
Pharmacogenet Genomics; 2008 Nov; 18(11):927-36. PubMed ID: 18854775
[TBL] [Abstract][Full Text] [Related]
13. Combined catechol-O-methyltransferase and mu-opioid receptor gene polymorphisms affect morphine postoperative analgesia and central side effects.
Kolesnikov Y; Gabovits B; Levin A; Voiko E; Veske A
Anesth Analg; 2011 Feb; 112(2):448-53. PubMed ID: 21127283
[TBL] [Abstract][Full Text] [Related]
14. [Genetic variation-- important for the clinical effect of opioids?].
Klepstad P; Dale O; Borchgrevink PC; Kaasa S; Skorpen F
Tidsskr Nor Laegeforen; 2005 Oct; 125(19):2655-8. PubMed ID: 16215614
[TBL] [Abstract][Full Text] [Related]
15. A118G single nucleotide polymorphism of human mu-opioid receptor gene influences pain perception and patient-controlled intravenous morphine consumption after intrathecal morphine for postcesarean analgesia.
Sia AT; Lim Y; Lim EC; Goh RW; Law HY; Landau R; Teo YY; Tan EC
Anesthesiology; 2008 Sep; 109(3):520-6. PubMed ID: 18719451
[TBL] [Abstract][Full Text] [Related]
16. The value of CYP2D6 and OPRM1 pharmacogenetic testing for opioid therapy.
Reynolds KK; Ramey-Hartung B; Jortani SA
Clin Lab Med; 2008 Dec; 28(4):581-98. PubMed ID: 19059064
[TBL] [Abstract][Full Text] [Related]
17. A genetic association study of the functional A118G polymorphism of the human mu-opioid receptor gene in patients with acute and chronic pain.
Janicki PK; Schuler G; Francis D; Bohr A; Gordin V; Jarzembowski T; Ruiz-Velasco V; Mets B
Anesth Analg; 2006 Oct; 103(4):1011-7. PubMed ID: 17000822
[TBL] [Abstract][Full Text] [Related]
18. Clinical implications of opioid pharmacogenetics.
Argoff CE
Clin J Pain; 2010 Jan; 26 Suppl 10():S16-20. PubMed ID: 20026961
[TBL] [Abstract][Full Text] [Related]
19. The 118 A > G polymorphism in the human mu-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease.
Klepstad P; Rakvåg TT; Kaasa S; Holthe M; Dale O; Borchgrevink PC; Baar C; Vikan T; Krokan HE; Skorpen F
Acta Anaesthesiol Scand; 2004 Nov; 48(10):1232-9. PubMed ID: 15504181
[TBL] [Abstract][Full Text] [Related]
20. A possible genetic mechanism underlying individual and interstrain differences in opioid actions: focus on the mu opioid receptor gene.
Han W; Ide S; Sora I; Yamamoto H; Ikeda K
Ann N Y Acad Sci; 2004 Oct; 1025():370-5. PubMed ID: 15542738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
